• Je něco špatně v tomto záznamu ?

Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines

V. Králová, V. Hanušová, P. Staňková, K. Knoppová, K. Čáňová, L. Skálová,

. 2013 ; 24 (9) : 911-9.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14050890

This study aimed to test the antiproliferative effect of three benzimidazole anthelmintics in intestinal cancer cells and to investigate whether these drugs, which inhibit tubulin polymerization, can potentiate the efficacy of the microtubule-stabilizing drug paclitaxel (PTX). Four intestinal cancer cell lines, SW480, SW620, HCT8, and Caco2, with different origins and growth characteristics were used. The antiproliferative effect of albendazole (ABZ), ricobendazole (RBZ), flubendazole (FLU), and their combinations with PTX was tested using three different end-point viability assays, cell cycle distribution analysis, and the x-CELLigence System for real-time cell analysis. ABZ and FLU inhibited cell proliferation significantly in a concentration-dependent and time-dependent manner through cell arrest in the G2/M phase. RBZ was not effective at any concentration tested. The cell lines differed in sensitivity to FLU and ABZ, with HCT8 being the most sensitive, showing IC₅₀ values for ABZ and FLU that reached 0.3 and 0.9 μmol/l, respectively. Combinations of PTX+ABZ and PTX+FLU decreased cell viability more effectively when compared with treatment with individual drugs alone. The anthelmintic benzimidazole drugs ABZ and FLU show a significant cytostatic effect and potentiate the efficacy of PTX in intestinal cancer cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14050890
003      
CZ-PrNML
005      
20140408110952.0
007      
ta
008      
140401s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/CAD.0b013e3283648c69 $2 doi
035    __
$a (PubMed)23884106
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Králová, Věra
245    10
$a Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines / $c V. Králová, V. Hanušová, P. Staňková, K. Knoppová, K. Čáňová, L. Skálová,
520    9_
$a This study aimed to test the antiproliferative effect of three benzimidazole anthelmintics in intestinal cancer cells and to investigate whether these drugs, which inhibit tubulin polymerization, can potentiate the efficacy of the microtubule-stabilizing drug paclitaxel (PTX). Four intestinal cancer cell lines, SW480, SW620, HCT8, and Caco2, with different origins and growth characteristics were used. The antiproliferative effect of albendazole (ABZ), ricobendazole (RBZ), flubendazole (FLU), and their combinations with PTX was tested using three different end-point viability assays, cell cycle distribution analysis, and the x-CELLigence System for real-time cell analysis. ABZ and FLU inhibited cell proliferation significantly in a concentration-dependent and time-dependent manner through cell arrest in the G2/M phase. RBZ was not effective at any concentration tested. The cell lines differed in sensitivity to FLU and ABZ, with HCT8 being the most sensitive, showing IC₅₀ values for ABZ and FLU that reached 0.3 and 0.9 μmol/l, respectively. Combinations of PTX+ABZ and PTX+FLU decreased cell viability more effectively when compared with treatment with individual drugs alone. The anthelmintic benzimidazole drugs ABZ and FLU show a significant cytostatic effect and potentiate the efficacy of PTX in intestinal cancer cells.
650    _2
$a adenokarcinom $x farmakoterapie $7 D000230
650    _2
$a albendazol $x analogy a deriváty $x farmakologie $7 D015766
650    _2
$a anthelmintika $x farmakologie $7 D000871
650    _2
$a antitumorózní látky $x farmakologie $7 D000970
650    _2
$a antitumorózní látky fytogenní $x farmakologie $7 D000972
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a synergismus léků $7 D004357
650    _2
$a G2 fáze $x účinky léků $7 D016195
650    _2
$a lidé $7 D006801
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a střevní nádory $x farmakoterapie $7 D007414
650    _2
$a mebendazol $x analogy a deriváty $x farmakologie $7 D008463
650    _2
$a mikrotubuly $x účinky léků $7 D008870
650    _2
$a paclitaxel $x farmakologie $7 D017239
650    _2
$a stabilita proteinů $x účinky léků $7 D055550
650    _2
$a modulátory tubulinu $x farmakologie $7 D050257
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hanušová, Veronika $u -
700    1_
$a Staňková, Petra $u -
700    1_
$a Knoppová, Kateřina $u -
700    1_
$a Čáňová, Kristýna $u -
700    1_
$a Skálová, Lenka $u -
773    0_
$w MED00179775 $t Anti-cancer drugs $x 1473-5741 $g Roč. 24, č. 9 (2013), s. 911-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23884106 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140401 $b ABA008
991    __
$a 20140408111040 $b ABA008
999    __
$a ok $b bmc $g 1018026 $s 849470
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 24 $c 9 $d 911-9 $i 1473-5741 $m Anticancer Drugs $n Anticancer Drugs $x MED00179775
LZP    __
$a Pubmed-20140401

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace